- Home
- API vs DMAC Comparison
API vs DMAC Comparison
Compare API & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | API | DMAC |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.2M | 428.6M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | API | DMAC |
|---|---|---|
| Price | $3.58 | $7.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 365.6K | 176.4K |
| Earning Date | 03-02-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $13.74 | N/A |
| Revenue Next Year | $16.46 | N/A |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.53 | $3.22 |
| 52 Week High | $5.15 | $10.42 |
Technical Indicators
Market Signals| Indicator | API | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 25.94 | 32.42 |
| Support Level | $3.37 | $6.56 |
| Resistance Level | $4.02 | $7.30 |
| Average True Range (ATR) | 0.21 | 0.42 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 3.13 | 18.15 |
Price Performance
Historical ComparisonAbout API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.